Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity

v3.23.3
Stockholders Equity
9 Months Ended
Sep. 30, 2023
Stockholders Equity [Abstract]  
STOCKHOLDERS EQUITY

NOTE 8 – STOCKHOLDERS EQUITY

 

  A. Share Capital:

 

Private Investment in Public Equity:

 

On February 22, 2023, the Company entered into a Securities Purchase Agreement to issue and sell an aggregate of 15,997,448 shares of its Common Stock and 14,610,714 pre-funded warrants (the “Pre-Funded Warrants”, and collectively, the “Securities”) at a price of $0.245 per share and $0.244 per Pre-Funded Warrant, through a PIPE. The gross proceeds from this offering are approximately $7,485, before deducting issuance costs. The offering closed in two parts. The first closing, which covered 3,199,491 shares of Common Stock and 2,776,428 Pre-Funded Warrants for gross proceeds of $1,469, occurred on February 27, 2023. Such Pre-Funded Warrants became exercisable on February 27, 2023, at an exercise price of $0.001 per share of Common Stock and have no expiration date. At the first closing, the Company raised net proceeds of $1,293, after deducting issuance costs of $176. On April 24, 2023, the Company’s stockholders approved the issuance of up to 24,632,243 shares of Common Stock, comprised of shares and shares underlying Pre-Funded Warrants, in accordance with NYSE American rules. On May 4, 2023, the Company completed the second closing of the offering and issued an aggregate of 12,797,957 shares of Common Stock and 11,834,286 Pre-Funded Warrants. Such Pre-Funded Warrants became exercisable on May 4, 2023, at an exercise price of $0.001 per share of Common Stock and have no expiration date. At the second closing, the Company raised net proceeds of $5,859, after deducting issuance costs of $157. As of September 30, 2023, no Pre-Funded Warrants were exercised.

 

The exercise of the outstanding Pre-Funded Warrants is subject to a beneficial ownership limitation between 9.90%-9.99%, The exercise price and number of shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants are subject to adjustment in the event of any stock dividends, stock splits, reverse stock split and reclassification, as described in the agreements. Pursuant to the sole discretion of the holder, the Pre-Funded Warrants may be exercisable on a “cashless” basis. The Pre-Funded Warrants were classified as a component of stockholders’ equity.

 

At-the-market Sales Agreement:

 

In December 2020, pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock with an aggregate offering price of up to $50,000 (subsequently reduced to $19,950), with Jefferies acting as sales agent. During the nine months ended September 30, 2023, the Company did not sell any shares of Common Stock under the ATM Agreement. During the nine months ended September 30, 2022, the Company sold 229,044 shares of Common Stock under the ATM Agreement, at an average price of $1.19 per share, raising aggregate net proceeds of approximately $273, after deducting an aggregate commission of $8.

 

CFF Agreement:

 

In December 2021, the Company entered into a Securities Purchase Agreement with the Cystic Fibrosis Foundation (“CF Foundation”), an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company had the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion was less than $2.57, the Company had the right in its sole discretion to waive the second tranche payment and in such event, the CF Foundation would not have had any right to receive additional shares. The Company waived its right to receive the second tranche of $2,000 mentioned above, as the CF Foundation participated in the PIPE and invested an aggregate amount of $2,000.

 

Preferred Stock:

 

The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors (the “Board”). 

 

Warrants:

 

As of September 30, 2023, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:

 

Warrant   Issuance Date   Expiration Date   Exercise
Price Per
Share
    Number of
Shares of
Common
Stock
Underlying
Warrants
 
Private Placement Warrants   IPO (December 13, 2018)   December 13, 2023     11.50       2,900,000  
Public Warrants   IPO (December 13, 2018)   October 28, 2024     11.50       3,500,000  
2021 Registered Direct Offering Warrants   SPA (July 28, 2021)   January 28, 2027     5.00       2,812,501  
Pre-Funded Warrants   February 27, 2023   -     0.001       2,776,428  
Pre-Funded Warrants   May 4, 2023   -     0.001       11,834,286  
                      23,823,215  

 

  B. Stock-based Compensation:

 

On August 21, 2023, the Board of Directors approved the grant of 82,000 options to two directors under the Company’s 2019 Omnibus Long-Term Incentive Plan (the “2019 Plan”), without consideration. Options were granted at an exercise price of $0.363 per share with a vesting period of four years. Directors are entitled to full acceleration of their unvested options upon the occurrence of both a change in control of the Company and the end of their engagement with the Company.

 

On March 1, 2023, the Board of Directors approved the grant of 1,543,000 options to 49 employees, five senior officers and three directors under the 2019 Plan, without consideration. The options were granted at an exercise price of $0.40 per share with a vesting period of four years. Directors and senior officers are entitled to full acceleration of their unvested options upon the occurrence of both a change in control of the Company and the end of their engagement with the Company. 

 

The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:

 

    Nine Months Ended
September 30,
 
    2023     2022  
Underlying value of Common Stock ($)     0.36-0.40       0.37-1.41  
Exercise price ($)     0.36-0.40       0.37-1.41  
Expected volatility (%)     94.3-96.6       85.3-88.4  
Expected terms of the option (years)     6.11       5.31-6.11  
Risk-free interest rate (%)     4.21-4.44       2.50-4.05  

 

The cost of the benefit embodied in the options granted during the nine months ended September 30, 2023, based on their fair value as of the grant date, is estimated to be approximately $510. These amounts will be recognized in statements of operations over the vesting period.

 

(1) A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:

 

    For the Nine Months Ended
September 30, 2023
 
    Number of
Options
    Weighted
Average
Exercise Price
    Aggregate
Intrinsic
Value
 
Outstanding at the beginning of period     4,769,441     $ 2.93     $ 40  
Granted     1,625,000     $ 0.40          
Forfeited     (329,860 )   $ 2.32          
Expired     (154,245 )   $ 4.69          
Exercised    
-
    $
-
         
Outstanding at the end of period     5,910,336     $ 2.22     $ 76  
Exercisable at the end of period     3,234,658     $ 3.02          
Weighted average remaining contractual life of outstanding options – years as of September 30, 2023     7.03                  

 

Warrants:

 

As of September 30, 2023, the Company had the following outstanding compensation related warrants to purchase Common Stock:

 

Warrant   Issuance
Date
  Expiration
Date
    Exercise
Price
Per Share
    Number of
Shares of
Common Stock
Underlying
Warrants
 
Private Warrants issued to scientific founders (see below)   November 27, 2017    
        -
     
         -
      2,974  

 

  In November 2017, BiomX Israel issued 2,974 warrants to its scientific founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price.

 

(2) The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2023     2022     2023     2022  
Research and development expenses, net     31       104       202       352  
General and administrative     164       259       439       810  
      195       363       641       1,162